Patents by Inventor James B. Dale
James B. Dale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9650425Abstract: Immunogenic group A streptococcus M-related polypeptides and peptides and immunogenic compositions comprising these M-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-GAS and anti-SDSE antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise M-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group A streptococcus immunogen, such as an M peptide or Spa peptide.Type: GrantFiled: February 11, 2014Date of Patent: May 16, 2017Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: James B. Dale, Harry S. Courtney
-
Patent number: 9254317Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: GrantFiled: February 10, 2014Date of Patent: February 9, 2016Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Publication number: 20140227313Abstract: Immunogenic group A streptococcus M-related polypeptides and peptides and immunogenic compositions comprising these M-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-GAS and anti-SDSE antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise M-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group A streptococcus immunogen, such as an M peptide or Spa peptide.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Inventors: James B. Dale, Harry S. Courtney
-
Publication number: 20140220066Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: ApplicationFiled: February 10, 2014Publication date: August 7, 2014Applicant: University of Tennessee Research FoundationInventor: James B. Dale
-
Patent number: 8697085Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: GrantFiled: June 15, 2012Date of Patent: April 15, 2014Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Publication number: 20120321657Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: ApplicationFiled: June 15, 2012Publication date: December 20, 2012Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventor: James B. Dale
-
Publication number: 20090035259Abstract: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.Type: ApplicationFiled: June 27, 2008Publication date: February 5, 2009Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventor: James B. Dale
-
Patent number: 7402316Abstract: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.Type: GrantFiled: February 17, 2004Date of Patent: July 22, 2008Assignee: University of Tennessee Research FoundationInventor: James B Dale
-
Patent number: 7270827Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.Type: GrantFiled: October 28, 2002Date of Patent: September 18, 2007Assignees: University of Tennessee Research Foundation, ID Biomedical Corporation of WashingtonInventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
-
Patent number: 7255863Abstract: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.Type: GrantFiled: January 16, 2004Date of Patent: August 14, 2007Assignee: University of Tennessee Research FoundationInventor: James B Dale
-
Patent number: 7160547Abstract: Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.Type: GrantFiled: October 9, 2002Date of Patent: January 9, 2007Assignee: University of Tennessee Research CorporationInventor: James B Dale
-
Patent number: 7074416Abstract: Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.Type: GrantFiled: May 7, 2002Date of Patent: July 11, 2006Assignee: University of Tennessee Research FoundationInventor: James B Dale
-
Patent number: 7063850Abstract: The present invention provides the discovery of a new Streptococcus protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are protective against multiple serotypes of streptococci. The invention further provides isolated Spa polypeptides, proteins, peptides, and antibodies against the same, as well as nucleic acids encoding Spa polypeptide and peptide antigens. Also provided are methods for identification and isolation of a Spa polypeptide, therapeutic compositions comprised of Spa antigens or antibodies and methods of their use in protecting an animal against a Streptococcus infection.Type: GrantFiled: December 22, 1999Date of Patent: June 20, 2006Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Patent number: 6716433Abstract: The present invention provides immunogenic synthetic fusion polypeptide which stimulates an immune response against a selected pathogen, comprising at least two immunogenic polypeptides from a Group A streptococci of at least 10 amino acids in length which are capable of stimulating an immune response against Group A strepococci, and a peptide C terminal to the immunogenic polypeptide which protects the immunogenicity of the immunogenic portion, wherein the C-terminal peptide is not required to stimulate an immune response against Group A streptococci.Type: GrantFiled: September 10, 1998Date of Patent: April 6, 2004Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Publication number: 20030157122Abstract: Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.Type: ApplicationFiled: October 9, 2002Publication date: August 21, 2003Applicant: University of Tennessee Research CorporationInventor: James B. Dale
-
Publication number: 20030143245Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.Type: ApplicationFiled: October 28, 2002Publication date: July 31, 2003Applicant: University of Tennessee Research CorporationInventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
-
Publication number: 20020176863Abstract: Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.Type: ApplicationFiled: May 7, 2002Publication date: November 28, 2002Applicant: University of Tennessee Research CorporationInventor: James B. Dale
-
Patent number: 6419932Abstract: Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.Type: GrantFiled: August 19, 1997Date of Patent: July 16, 2002Assignee: University of Tennessee Research CorporationInventor: James B. Dale
-
Publication number: 20020086023Abstract: Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.Type: ApplicationFiled: October 10, 2001Publication date: July 4, 2002Applicant: University of Tennessee Research CorporationInventor: James B. Dale
-
Patent number: 6063386Abstract: A recombinant multivalent hybrid protein vaccine against multiple serotypes of group A streptococci that may result in rheumatic fever. The vaccine can also evoke other protective antibodies of the mucosal type DNA sequences e.g. genes which encode the necessary amino acids that carry our the desired epitopes. A method of vaccination against streptococcal infections and compositions for carrying out the same.Type: GrantFiled: September 15, 1997Date of Patent: May 16, 2000Assignee: University of Tennessee Research CorporationInventors: James B. Dale, James W. Lederer